Attached files

file filename
8-K - FORM 8-K - Element Solutions Incf8k_102714.htm
EX-99.1 - EXHIBIT 99.1 - Element Solutions Incexh_991.htm
EX-99.2 - EXHIBIT 99.2 - Element Solutions Incexh_992.htm
EX-99.3 - EXHIBIT 99.3 - Element Solutions Incexh_993.htm
EX-23.1 - EXHIBIT 23.1 - Element Solutions Incexh_231.htm
Exhibit 99.4
 
UNAUDITED PRO FORMA FINANCIAL INFORMATION
 
On October 31, 2013, we completed our acquisition of substantially all of the outstanding equity of MacDermid, Incorporated (“MacDermid”) for approximately $1.8 billion (including the assumption of approximately $754 million of indebtedness, consisting primarily of MacDermid’s first lien credit facility), plus (i) approximately $100 million of contingent consideration tied to achieving certain EBITDA and stock trading price performance metrics over a seven year period following the closing of the acquisition and (ii) an interest in certain MacDermid pending litigation (the “MacDermid Acquisition”).
 
At the closing of the MacDermid Acquisition on October 31, 2013, we paid approximately $925 million in cash and delivered approximately $100 million of new equity. The equity issued primarily consisted of shares of common stock of a then wholly-owned subsidiary of Platform that may be exchanged for shares of Platform common stock at future specified dates beginning one year after the closing. In addition, we acquired the remaining 3% of MacDermid in March 2014, pursuant to the terms of an Exchange Agreement, dated October 25, 2013, between us and the fiduciaries of the MacDermid, Incorporated Profit Sharing and Employee Savings Plan (the “401K Plan”). Most of the 401K Plan participants received shares of our common stock for their interests in MacDermid. We funded the cash portion of the purchase price and related transaction expenses with a combination of cash on hand and approximately $137 million of proceeds from a warrant exchange offer.
 
On November 3, 2014, we completed the acquisition of certain legal entities and other assets and liabilities that comprise the Chemtura AgroSolutions business (“CAS”), from Chemtura Corporation, a Delaware corporation (“Chemtura”), (the “CAS Acquisition”), for approximately $1 billion, consisting of $950 million in cash, subject to working capital and other adjustments, plus two million shares of Platform common stock, $.01 par ("CAS Shares"). We funded the cash portion of the purchase price and related transaction expense with a combination of cash on hand and approximately $389 million of senior term debt under our Second Amended and Restated Credit Agreement ("Second Amendment"), approximately $259 million of which is expected to be denominated in Euros.
 
In October 2014, we entered into the Arysta Acquisition Agreement to acquire all of the outstanding common stock of Arysta ("Arysta") for approximately $3.5 billion, consisting of $2.9 billion of cash and $600 million of convertible preferred stock.  We intend to fund the cash portion of the purchase price and related transaction expenses with a combination of cash on hand, the proceeds from the issuance of common stock of $350 million ("Common Stock Offering"), $900 million of senior unsecured notes ("Bonds"), and $1.1 billion of senior secured term debt ("Incremental Term Debt").
 
 
 

 
 
The unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2014 and for the fiscal year ended December 31, 2013 give effect to the MacDermid Acquisition, CAS Acquisition, and the Arysta Acquisition as if they had been consumated on January 1, 2013. The unaudited pro forma condensed combined balance sheet as of June 30, 2014 gives effect to the CAS Acquisition and Arysta Acquisition as if it had been consumated on June 30, 2014.
 
The following unaudited pro forma condensed consolidated balance sheet as of June 30, 2014 and the unaudited pro forma condensed consolidated statement of operations for the six months ended June 30, 2014 were derived from our unaudited consolidated financial statements and the unaudited combined and consolidated statement of operations of CAS and Arysta, respectively. The following unaudited pro forma condensed consolidated statement of operations for the year ended December 31, 2013 (inclusive of both the Successor 2013 and Predecessor 2013 Periods) were derived from our consolidated statement of operations and the audited consolidated statement of operations of CAS and Arysta. The unaudited pro forma statements of operations and balance sheet do not reflect the completed acquisition on October 1, 2014 of Percival S.A., a Belgium société anonyme ("Percival"), including Percival's agrochemical business, Agriphar, or the related financing because the acquisition is not significant as defined by Rule 3-05 of Regulation S-X. The unaudited pro forma condensed consolidated financial information presented below should be read in conjunction with our “Management's Discussion and Analysis of Financial Condition and Results of Operations.”
 
The pro forma adjustments are described in the accompany notes and include the following:
 
 The preliminary allocation of the purchase price to the CAS balance sheet as shown below:
 
(in millions)
 
Current assets
  $ 346    
Identifiable intangible assets
    440    
Goodwill
    316    
Property, plant, and equipment
    14    
Other long-term assets
    6    
Total assets
  $ 1,122    
Current liabilities
    81    
Other liabilities
    42    
Total liabilities
  $ 123    
Total consideration
  $ 999    
 
 The preliminary allocation of the purchase price to the Arysta balance sheet as shown below:
 
(in millions)
 
Current assets
  $ 1,296    
Identifiable intangible assets
    1,596    
Goodwill
    1,757    
Property, plant, and equipment
    81    
Other long-term assets
    100    
Total assets
  $ 4,830    
Current liabilities
    577    
Other liabilities
    562    
Total liabilities
  $ 1,139    
Noncontrolling interest
    60    
Total liabilities and noncontrolling interest
  $ 1,199    
Total consideration
  $ 3,631    
 
The Company has not completed the detailed valuations necessary to estimate the fair value of the assets acquired and the liabilities expected to be acquired in the CAS Acquisition, the Arysta Acquisition, and the related allocations of purchase price. Additionally, a final determination of the fair value of assets acquired and liabilities acquired will be based on the actual net tangible and intangible assets and liabilities of CAS and Arysta that exist as of the dates of the CAS Acquisition and Arysta Acquisition. Accordingly, the pro forma purchase price adjustments are preliminary and are subject to further adjustments as additional information becomes available and as additional analyses are performed. As the final valuations are performed, increases or decreases in the fair value of relevant balance sheet amounts and their useful lives will result in adjustments, which may be material, to the balance sheet and/or the statement of operations.
 
 
 

 
 
Pro forma adjustments to historical financial information are subject to assumptions described in the notes following the unaudited proforma financial statements. Management believes that these assumptions and adjustments are reasonable and appropriate under the circumstances and are factually supported based on information currently available. The principal adjustments consist of the following:
 
 
-
The completion of the MacDermid Acquisition, CAS Acquisition, and Arysta Acquisition for the statements of operations, and the completion of the CAS Acquisition and Arysta Acquisition for the balance sheet in each case because the MacDermid Acquisition is included in the condensed consolidated balance sheet as of June 30, 2014;
     
 
-
Borrowings under the Second Amendment;
     
 
-
The issuance of 25.5 million shares (defined terms) of Platform common stock ("PIPE");
     
 
-
The anticipated financing related to the Arysta Acquisition in the form of the Common Stock Offering, Bonds, and Incremental Term Debt, which is backed by committed bridge financing of $2.3 billion, ("Bridge Financing").
     
 
-
The amendment to and assumption of MacDermid's first lien credit facility for the MacDermid Acquisition and the amendment to such facility in connection with the CAS Acquisition;
     
 
-
An adjustment to the results of operations to remove Platform's recording of a one-time, non-cash expense estimated to be approximately $172 million upon the closing of the MacDermid Acquisition, which represents the fair value of the founder preferred dividend rights at that time, as this will not have an ongoing impact on the statement of operations. Future dividends payable in Platform common shares will be recorded in equity.
 
The unaudited pro forma condensed consolidated financial statements are for illustrative and informational purposes only and are not intended to represent, or be indicative of, what our financial position or results of operations would have been had the transactions occurred on the dates indicated. The unaudited pro forma condensed consolidated financial information also should not be relied upon as a representation of our future performance.
 
 
 

 
 
PLATFORM SPECIALTY PRODUCTS CORPORATION
UNAUDITED PRO FORMA BALANCE SHEET AS OF JUNE 30, 2014
 
(In thousands)
 
Platform
(Historical)
   
CAS
(Historical)
   
Arysta
(Historical)
   
CAS
Adjustments
   
Arysta
Adjustments
   
Common
Stock
Offering(1)
    Bonds(1)    
Incremental
Term
Debt(1)
   
Pro forma
Balance
Sheet
 
Assets
                                                             
 
                                                             
Cash and cash equivalents
  $ 642,760     $ 7,825     $ 184,207     $ 386,975  
CA
$       $       $       $       $    
                              651,400  
CB
                                     
                              (3,226 )
CC
  (124,207 )
AA
                  1,089,000  
TA
     
                              (950,000 )
CD
  (2,910,000 )
AB
  339,500  
UA
  884,250  
BA
  (13,750 )
TB
  184,734  
Accounts receivable, net
    142,011       205,777       738,722          
 
                                  1,086,510  
Inventories
    80,511       102,822       301,647       34,758  
CE
     
 
                             
                              (25,583 )
CF
  135,741  
AC
                          629,896  
Prepaid expenses and other current assets
    24,262       20,434       59,650               (6,000 )
AD
                             
                                      25,638  
AE
                             
                                      2,457  
AF
                          126,441  
Total current assets
    889,544       336,858       1,284,226       94,324       (2,876,371 )     339,500       884,250       1,075,250       2,027,581  
                                                                         
Property, plant, and equipment, net
    133,641       23,799       81,029       (10,206 )
CG
                                  228,263  
Goodwill
    1,004,354               831,862       276,781  
CH
  (831,862 )
AG
                             
                              39,097  
CI
  1,403,586  
AH
                             
                                      353,413  
AI
                          3,077,232  
Intangible assets, net
    699,443       29,306       568,762       (29,306 )
CJ
  (568,762 )
AJ
                             
                              440,000  
CK
  1,596,000  
AK
                          2,735,443  
Other assets
    39,707       9,666       99,922       2,726  
CC
                                     
                              (4,064 )
CL
                  15,750  
BA
  9,827  
TB
  173,534  
Total Assets
  $ 2,766,689     $ 399,629     $ 2,865,801     $ 809,352     $ (923,996 )   $ 339,500     $ 900,000     $ 1,085,077     $ 8,242,052  
                                                                         
Liabilities and Shareholders' Equity
                                                                       
 
                                                                       
Current portion of long-term debt and capital leases
    7,953               56,336       3,890  
CM
  (56,336 )
AL
                  11,000  
TC
  22,843  
Accounts payable, accrued expenses, and other
    107,372       80,680       576,857               (6,000 )
AD
                          758,909  
Total current liabilities
    115,325       80,680       633,193       3,890       (62,336 )     -       -       11,000       781,752  
                                                                         
Long-term debt and capital lease obligations
    740,497               1,758,900       386,975  
CA
                          1,089,000  
TA
     
                              (3,890 )
CM
  (1,758,900 )
AL
          900,000  
BA
  (11,000 )
TC
  3,101,582  
Other long-term liabilities
    284,666       2,749       198,434       39,097  
CI
  353,413  
AI
                             
                                      25,638  
AE
                             
                                      10,000  
AN
                             
                                      2,457  
AF
                             
                                      183,950  
AM
                          1,100,404  
Total Liabilities
    1,140,488       83,429       2,590,527       426,072       (1,245,778 )     -       900,000       1,089,000       4,983,738  
                                                                         
Stockholder's Equity
                                                                       
Preferred shares - Class A
    20                                                               20  
Preferred shares - Class B
                                    6  
AM
                          6  
Common shares
    1,353                       20  
CN
                                     
                              255  
CB
          144  
UA
                  1,772  
Additional paid in capital
    1,703,483               1,065,779       48,560  
CN
  (1,065,779 )
AO
                             
                              651,145  
CB
  536,987  
AM
  339,356  
UA
          (3,923 )
TB
  3,275,608  
Retained deficit
    (202,016 )             (828,228 )     (500 )
CC
  838,228  
AO
                             
                                      (10,000 )
AN
                          (202,516 )
Accumulated other comprehensive income
    24,372               6,184               (6,184 )
AO
                          24,372  
Parent net investment
            316,200               (316,200 )
CO
                                     
Total stockholders' equity
    1,527,212       316,200       243,735       383,280       293,258       339,500       -       (3,923 )     3,099,262  
Noncontrolling interests
    98,989               31,539               28,524  
AP
                          159,052  
Total equity
    1,626,201       316,200       275,274       383,280       321,782       339,500       -       (3,923 )     3,258,314  
Total liabilties and stockholders' equity
  $ 2,766,689     $ 399,629     $ 2,865,801     $ 809,352     $ (923,996 )   $ 339,500     $ 900,000     $ 1,085,077     $ 8,242,052  
 
(1) Platform anticipates financing a portion of the cash consideration for the Arysta Acquisition with the Common Stock Offering, Bonds, and Incremental Term Debt as reflected in this pro forma balance sheet. Platform also has committed Bridge Financing; however, we believe it is unlikely that the Bridge Financing will be drawn upon.
 
 
 

 
 
PLATFORM SPECIALTY PRODUCTS CORPORATION
UNAUDITED PRO FORMA STATEMENT OF OPERATIONS
FOR THE SIX MONTHS ENDED JUNE 30, 2014
 
    Platform (Historical)    
CAS
(Historical)
(1)
   
Arysta
(Historical)
(2)
   
CAS
Adjustments
(3)
   
Arysta
Adjustments
    Bonds(4)    
Incremental
Term Debt(4)
   
Pro forma Consolidated
   
                                                                   
(In thousands except per share data)
                                                                 
Net sales
  $ 372,858     $ 240,134     $ 699,646     $       $       $       $       $ 1,312,638    
Cost of sales
    191,949       142,746       438,958       (11,956 )
CP
                          761,697    
Gross profit
    180,909       97,388       260,688       11,956       -       -       -       550,941    
                                                                   
Operating expenses:
                                                                 
Selling, technical, general, and administrative
                                                                 
      158,811       43,349       172,115       (9,600 )
CQ
                               
                              (2,684 )
CR
  (28,479 )
AQ
                       
                              18,480  
CS
  67,000  
AR
                  418,992    
Research and development
    12,096       4,835       4,356                                       21,287    
Equity loss (income)
            144       (174 )     (144 )
CL
                          (174 )  
Other
    404               644                                       1,048    
Total operating expense
    171,311       48,328       176,941       6,052       38,521       -       -       441,153    
                                                                   
Operating profit
    9,598       49,060       83,747       5,904       (38,521 )                     109,788    
                                                                   
Other (expense) income:
                                                                 
Interest, net
    (15,404 )     (90 )     (45,085 )     93  
CT
                               
                              (8,510 )
CU
  79,782  
AS
  (29,250 )
BB
  (24,910 )
TD
  (43,374 )  
Other (expense) income, net
    (601 )     3,473       (22,185 )                                     (19,313 )  
      (16,005 )     3,383       (67,270 )     (8,418 )     79,782       (29,250 )     (24,910 )     (62,687 )  
                                                                   
(Loss) income before income taxes and non-controlling interests
    (6,407 )     52,443       16,477       (2,514 )     41,261       (29,250 )     (24,910 )     47,701    
Income tax benefit (provision)
    1,947       (18,537 )     (35,745 )     990  
CV
$ (12,539 )
AT
  8,889  
BC
  7,570  
TE
  (47,424 )  
Net (loss) income
    (4,460 )     33,906       (19,268 )     (1,523 )     28,722       (20,361 )     (17,340 )     (323 )  
Net (income) loss attributable to non-controlling interest
    (3,334 )             (3,625 )                                     (6,959 )  
Net (loss) income attributable to common shareholders
  $ (7,794 )   $ 33,906     $ (22,893 )   $ (1,523 )   $ 28,722     $ (20,361 )   $ (17,340 )   $ (7,282 )  
                                                                   
(Loss) Earnings Per Share
                                                                 
Basic
  $ (0.07 )     n/a       n/a       n/a       n/a       n/a       n/a     $ (0.04 )  
Diluted
  $ (0.07 )     n/a       n/a       n/a       n/a       n/a       n/a     $ (0.04 )  
                                                                   
Weighted average shares outstanding (millions)
                                                                 
Basic
    118       n/a       n/a       n/a       n/a       n/a       n/a       163  
SA
Diluted
    118       n/a       n/a       n/a       n/a       n/a       n/a       163  
SB
 
(1) The historical statement of operations of CAS presents cost of goods sold (excluding depreciation) of $138,885 as an operating expense. For purposes of this pro forma, this amount plus $3,861 of related depreciation is presented as cost of sales to present gross profit for the business to be acquired.
(2) Adjustments to convert the IFRS basis to US GAAP basis are included in the Arysta adjustments column.
(3) The CAS Adjustment column includes adjustment CP for the ongoing effect of the MacDermid Acquisition that is otherwise included in the Platform historical amounts for the six months ended June 30, 2014.
(4) Platform anticipates financing a portion of the cash consideration for the Arysta acquisition with the Common Stock Offering, Bonds, and Incremental Term Debt as reflected in this pro forma balance sheet. Platform also has Bridge Financing available; however, we believe it is unlikely that the Bridge Financing will be drawn upon. If Platform is unavailable to finance a portion of the cash consideration for Arysta as anticipated, the net loss to common shareholders on a pro forma basis may increase by up to approximately $25 million. The amount of loss is dependent on several factors, including the terms of the Bridge Financing and whether alternative sources of equity or debt financing are available.
 
 
 

 
 
PLATFORM SPECIALTY PRODUCTS CORPORATION
UNAUDITED PRO FORMA STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 2013
 
     
Platform (Historical) (1)
 
MacDermid (Historical) (2)
 
Combined Successor and Predecessor Income Statement
 
CAS
(Historical)
(3)
   
Arysta
(Historical)
(4)
 
MacDermid Adjustments
   
CAS
Adjustments
 
Arysta
Adjustments
   
Bonds
(5)
   
 
Incremental
Term
Debt (5)
   
Pro forma Consolidated
 
     
Successor
 
Predecessor
                                                 
(In thousands except per share data)
                                                         
Net sales
$
 118,239
 $
 627,712
 $
 745,951
 
 $
 449,255
 
 $
 1,508,925
 $
 
 
 $
 
 $
   
 $
   
 $
   
 $
 2,704,131
 
Cost of sales
 
 82,587
 
 304,875
 
 387,462
   
 282,673
   
 979,335
 
 (23,912)
 MA
                           
                             
 3,226
 MB
           
 
         
 1,628,784
 
Gross profit
 
 35,652
 
 322,837
 
 358,489
   
 166,582
   
 529,590
 
 20,686
   
 -
 
 -
   
 -
   
 -
   
 1,075,347
 
                                                             
Operating expenses:
                                                         
 
Selling, technical, general, and administrative
 
 54,521
 
 207,554
 
 262,075
   
 71,778
   
 338,893
 
 (247)
 MC
                           
                             
 (9,317)
 MD
                           
                             
 (32,125)
 ME
                           
                             
 (31,254)
 MF
                           
                             
 57,500
 MG
 
 (6,796)
CR
 (56,958)
 AQ
                 
                             
 626
 MB
 
 36,960
CS
 134,000
 AR
             
 765,135
 
 
Non-cash charge related to preferred stock dividend rights
 
 172,006
 
 
 
 172,006
   
 
       
 (172,006)
 MH
 
 
 
 
               
 
 
                         
 
                             
 
 
 
Research and development
 
 3,995
 
 19,898
 
 23,893
   
 13,243
   
 8,866
 
 (24)
 MB
 
 
 
 
               
 45,978
 
 
Equity income
 
 
 
 
 
 
   
 (1,020)
   
 (783)
 
 
   
 1,020
 CL
 
               
 (783)
 
 
Other
 
 762
 
 3,636
 
 4,398
   
 (271)
   
 45,030
 
 
   
 
 
 
   
 
   
 
   
 49,157
 
 
     Total operating expense
 
 231,284
 
 231,088
 
 462,372
   
 83,730
   
 392,006
 
 (186,847)
   
 31,184
 
 77,042
   
 -
   
 -
   
 859,487
 
                                                             
Operating (loss) profit
 
 (195,632)
 
 91,749
 
 (103,883)
   
 82,852
   
 137,584
 
 207,533
   
 (31,184)
 
 (77,042)
   
-
   
-
   
 215,860
 
                                                             
Other (expense) income:
                                                         
 
Interest, net
 
 (5,372)
 
 (45,929)
 
 (51,301)
   
 (208)
   
 (110,302)
 
 51,776
 MI
 
185
CT
                     
                             
 (30,631)
 MJ
 
(17,020)
CU
134,595
AS
 
(58,500)
BB
 
(49,819)
TD
 
(131,225)
 
 
Loss on extinguishment of debt
 
 
 
 (18,788)
 
 (18,788)
   
 
   
 
 
 
   
 
 
 
   
 
   
 
   
 (18,788)
 
 
Other (expense) income, net
 
 (440)
 
 (557)
 
 (997)
   
 (6,548)
   
 (61,020)
 
 
   
 
 
 
   
 
   
 
   
 (68,565)
 
     
 (5,812)
 
 (65,274)
 
 (71,086)
   
 (6,756)
   
 (171,322)
 
 21,145
   
 (16,835)
 
 134,595
   
 (58,500)
   
 (49,819)
   
 (218,578)
 
                                                             
(Loss) income before income taxes, non-controlling interests, and accrued payment-in-kind dividends on cumulative preferred shares
 
 (201,444)
 
 26,475
 
 (174,969)
   
 76,096
   
 (33,738)
 
 228,678
   
 (48,019)
 
 57,553
   
 (58,500)
   
 (49,819)
   
 (2,718)
 
                                                             
Income tax benefit (provision)
 
 5,819
 
 (12,961)
 
 (7,142)
   
 (29,241)
   
 (47,593)
 
 (16,014)
 MK
 
 17,668
 CV
($17,490)
AT
 
 17,778
BC
 
 15,140
TE
 
 (66,893)
 
Net (loss) income
 
 (195,625)
 
 13,514
 
 (182,111)
   
 46,855
   
 (81,331)
 
 212,664
   
 (30,351)
 
 40,063
   
 (40,722)
   
 (34,679)
   
 (69,611)
 
Net loss (income) attributable to non-controlling interests
 
 1,403
 
 (295)
 
 1,108
   
 
   
 (9,194)
 
 (861)
 ML
 
 
 
 
   
 
   
 
   
 (8,947)
 
                                                             
Net (loss) income attributable to shareholders
 
 (194,222)
 
 13,219
 
 (181,003)
   
 46,855
   
 (90,525)
 
 211,803
   
 (30,351)
 
 40,063
   
 (40,722)
   
 (34,679)
   
 (78,558)
 
Accrued payment-in-kind dividend on cumulative preferred shares
                                                         
     
 
 
 (22,454)
 
 (22,454)
   
 
   
 
 
 22,454
 MM
 
 
 
 
   
 
   
 
   
 
 
Net (loss) income attributable to common shareholders
$
 (194,222)
 $
 (9,235)
 $
 (203,457)
 
 $
 46,855
 
$
 (90,525)
$
 234,257
 
$
 (30,351)
$
 40,063
 
$
 (40,722)
 
 $
 (34,679)
 
 $
 (78,558)
 
                                                             
(Loss) Earnings Per Share
                                                         
Basic
$
 (2.10)
 
 n/a
 
 n/a
   
 n/a
   
 n/a
 
 n/a
   
 n/a
 
 n/a
   
 n/a
   
 n/a
 
$
 (0.54)
 
Diluted
$
 (2.10)
 
 n/a
 
 n/a
   
 n/a
   
 n/a
 
 n/a
   
 n/a
 
 n/a
   
 n/a
   
 n/a
 
$
 (0.54)
 
                                                             
Weighted average shares outstanding (millions)
                                                         
Basic
 
 93
 
n/a
 
n/a
   
n/a
   
n/a
 
n/a
   
n/a
 
n/a
   
n/a
   
n/a
   
146
 SC
Diluted
 
 93
 
n/a
 
n/a
   
n/a
   
n/a
 
n/a
   
n/a
 
n/a
   
n/a
   
n/a
   
146
 SD
 
(1) Historical Platform amounts included in the audited income statement of Platform reflect operations for the period from April 23, 2013 (date of inception) through December 31, 2013 (Successor Period).
(2) Historical MacDermid amounts included in the audited income statement of MacDermid reflect operations for the period from January 1, 2013 through October 31, 2013, date of acquisition by Platform (Predecessor Period).
(3) The historical statement of operations of CAS presents cost of goods sold (excluding depreciation) of $275,106 as an operating expense. For purposes of this pro forma, this amount plus $7,567 of related depreciation is presented as cost of sales to present gross profit for the business to be acquired.
(4) Adjustments to convert the IFRS basis to US GAAP basis are included in the Arysta adjustments column.
(5) Platform anticipates financing a portion of the cash consideration for the Arysta acquisition with the issuance of Common Stock Offering, Bonds, and Incremental Term Debt as reflected in this pro forma balance sheet. Platform also has committed Bridge Financing; however, we believe it is unlikely that the Bridge Financing will be drawn upon. If Platform is unavailable to finance a portion of the cash consideration for Arysta as anticipated, the net loss to common shareholders on a pro forma basis may increase by up to approximately $45 million. The amount of loss is dependent on several factors, including the terms of the Bridge Financing and whether alternative sources of equity or debt financing are available.
 
 
 

 
 
CAS Adjustments
 
CA
Reflects borrowings under the Second Amendment to finance a portion of the cash purchase price of CAS, net of estimated original issue discount of $2.1 million;
 
 
CB 
Represents net proceeds from the PIPE of Platform common stock, $.01 par, net of $0.25 million of issuance costs;
 
 
CC 
Reflects the deferred financing costs of $2.7 million and expenses of $0.5 million related to the borrowings under the Second Amendment to finance a portion of the CAS purchase price and for access to an incremental $125 million of revolving line of credit obtained in conjunction with the acquisition of CAS.
 
 
CD 
Reflects the cash paid to the sellers as part of the consideration for the CAS Acquisition.
 
 
CE 
Reflects management's preliminary estimate of the profit in CAS inventory step-up to fair value as of June 30, 2014.
 
 
CF 
Reflects raw materials and work-in-process inventory retained by Chemtura following the closing of the CAS Acquisition, in conjunction with supply agreements entered into with Chemtura.
 
 
CG 
Reflects the net book value of land and buildings retained by Chemtura.
 
 
CH 
Reflects the preliminary estimated goodwill associated with the CAS Acquisition excluding the effect of deferred taxes (see Note CI).  Such amount was calculated as the difference between the estimated allocation of purchase price to net tangible and intangible assets ($722 million) excluding the deferred tax liability calculated in Note CI and the total consideration paid for CAS ($999 million).
 
 
 

 
 
CI 
Reflects the estimated deferred tax liability associated with the temporary difference created by the preliminary step-up to fair value of intangible assets acquired of $111 million and other acquired tangible assets of $2.5 million less $2.8 million of tangible assets retained by Chemtura for financial reporting purposes that does not increase the related tax basis based upon the effective tax rate of CAS for the six months ended June 30, 2014.  The remaining step-up of intangibles and tangible assets does not create a temporary difference.
 
 
CJ 
Reflects the elimination of the historical intangibles of CAS.
 
 
CK 
Reflects management's preliminary estimated fair value of the intangible assets of CAS as of the closing of the CAS Acquisition:
 
 
 (In thousands)
       
 
Intangible Assets
       
 
Trade names-indefinite lives
  $ 5,000    
 
Technology (7-10 years)
  $ 85,000    
 
Customer relationships (8-20 years)
  $ 350,000    
 
CL 
Reflects investments in and related earnings of unconsolidated subsidiaries of CAS not acquired with the CAS Acquisition.
 
 
CM 
Reflects the reclassification of the Second Amendment that amortizes within a year.
 
 
CN 
Reflects issuance of the CAS shares to the sellers as part of the consideration for the CAS Acquisition based upon the closing price per share of Platform common stock as of October 17, 2014 of $24.29.
 
 
CO 
Reflects the elimination of historical CAS equity.
 
 
CP
Reflects the elimination of manufacturer's profits in inventory adjustments in connection with MacDermid of $11,956 for the six months ended June 30, 2014.

CQ
Reflects the elimination of non-recurring CAS acquisition-related expenses, including but not limited to financial advisory, legal and accounting fees, recorded during the six months ended June 30, 2014.
 
 
CR 
Reflects the elimination of the historical amortization expenses on CAS's intangible assets.
 
 
 

 
 
CS 
Reflects amortization expense to be recorded in conjunction with the estimated fair value of the intangible assets of CAS:
 
 
 (In thousands)
             
 
Intangible Assets
 
Estimated Fair Value
   
Annual Amortization
   
 
Trade names-indefinite lives
  $ 5,000     $    
 
Technology (7-10 years)
  $ 85,000     $ 10,250    
 
Customer relationships (8-20 years)
  $ 350,000     $ 26,710    
 
Annual amortization is calculated as estimated fair value divided by the calculated life of the related asset.

CT 
Reflects the elimination of interest expense related to debt not assumed from Chemtura in conjunction with the CAS Acquisition.
 
 
CU 
Reflects interest expense related to the Second Amendment funded a portion for the cash purchase price for the CAS Acquisition comprised of the following:
 
Interest on the incremental US Dollar borrowings under the first lien debt of $130 million at a rate of approximately 4.00% and on the Euro denominated first lien debt of $259 million equivalent at a rate of approximately 4.25% based on the terms of the credit agreement. These interest rates are based on an applicable margin of 3% applied to a LIBOR floor of 1% and are variable in nature.  The pre-tax effect of a 1/8% change effective interest rate would be $0.5 million annually.
 
Amortization of estimated deferred financing fees of $2 million and estimated original issuance discount of $2 million for the first lien term debt over the six year term of the loan.
 
Amortization of estimated deferred financing fees of $0.6 million for access to an incremental $125 million of revolving line of credit anticipated to be obtained in conjunction with the acquisition of CAS over the 4-year term of the facility.
 
 
CV
Reflects income tax benefit (expense) related to the income (loss) before income taxes, non-controlling interests, and accrued payment-in-kind dividends on cumulative preferred shares generated by the pro forma adjustments.  The tax rate applied is based upon the effective tax rate of CAS for the historical period presented of 38% and 35% for the year ended December 31, 2013 and the six months ended June 30, 2014, respectively. These rates were applied to acquisition costs, amortization, interest expense, and the earnings of unconsolidated subsidiaries not being acquired.
 
 
 

 
 
Arysta Adjustments
 
AA 
Reflects management's estimate of the amount of cash that will be retained by the seller of Arysta.

AB 
Reflects the cash to be paid to the sellers as part of the consideration for the Arysta Acquisition.
 
AC 
Reflects management's preliminary estimate of the profit in Arysta inventory step-up to fair value as of June 30, 2014.

AD
As Arysta financial statements are reported in IFRS, reflects management's estimate of the offset of derivative asset and liabilities required pursuant to US GAAP that is prohibited for IFRS.
 
  
AE 
As Arysta financial statements are reported in IFRS, reflects management's estimate of the offset of deferred tax assets and liabilities required pursuant to US GAAP that is prohibited for IFRS.
 
 
AF
Reflects management's estimate of deferred taxes related to intercompany profits that are reclassified as current assets pursuant to US GAAP.
 
  
AG
Reflects the elimination of Arysta's historical goodwill.
 
 
AH
Reflects the preliminary estimated goodwill associated with Arysta excluding the effect of deferred taxes (see Note AI).  Such amount was calculated as the difference between the estimated allocation of purchase price to net tangible and intangible assets ($2.2 billion) excluding the deferred tax liability calculated in Note AI and the total consideration paid for Arysta ($3.6 billion).
 
 
AI 
Reflects the estimated deferred tax liability associated with the preliminary step up to fair value of intangible assets, excluding goodwill related to acquisitions of stock of $969 million and other acquired tangible assets of $136 million based upon the effective tax rate of Platform for the six months ended June 30, 2014.
 
 
AJ 
Reflects the elimination of the historical intangibles at Arysta as of the closing of the Arysta Acquisition.
 
 
 

 
 
AK
Reflects management's preliminary estimated fair value of the intangible assets of Arysta as of the closing of the Arysta Acquisition:
 
 
(In thousands)
Intangible Assets
       
 
Trade names-indefinite lives
  $ 18,000    
 
Technology (7-10 years)
  $ 308,000    
 
Customer relationships (8-20 years)
  $ 1,270,000    
 
AL 
Reflects the elimination of debt not expected to be assumed in conjunction with the Arysta Acquisition.

AM
Reflects the issuance of $600 million of Platform preferred stock, $1,000 par, that is convertible into Platform common stock plus cash for the deficit, if any, between the value of our common stock and $27.14, to the sellers as part of the consideration for the Arysta Acquisition. The cash feature represents an embedded derivative liability of $184 million. Accordingly, additional paid in capital is adjusted for the difference between the fair value of Platform's common stock underlying the preferred stock of $537 million, which is based on Platform’s closing stock price of $24.29 as of October 17, 2014, less the par amount of the preferred stock.

AN
As Arysta financial statements are reported in IFRS, reflects management's estimate of uncertain tax positions pursuant to US GAAP that is not required for IFRS.

AO
Reflects elimination of Arysta historical equity which includes the $10 million adjustment in Note AN.

AP
Reflects management’s preliminary estimate of the fair value of the non-controlling interest of Arysta that is anticipated to remain outstanding subsequent to the Arysta Acquisition.
 
  
AQ 
Reflects elimination of historical amortization expenses related to Arysta's intangible assets.
 
 
AR
Reflects amortization expense to be recorded in conjunction with the estimated fair value of the intangible assets of Arysta:
 
 
(In thousands)
             
 
Intangible Assets
 
Estimated Fair Value
   
Annual Amortization
   
 
Trade names-indefinite lives
  $ 18,000     $    
 
Technology (7-10 years)
  $ 305,000     $ 36,300    
 
Customer relationships (8-20 years)
  $ 1,257,000     $ 94,700    
 
Annual amortization is calculated as estimated fair value divided by the calculated life of the related asset.
 
AS 
Reflects elimination of historical interest expense at Arysta for indebtedness not assumed at closing.

AT
Reflects income tax benefit (expense) related to the income (loss) before income taxes, non-controlling interests, and accrued payment-in-kind dividends on cumulative preferred shares generated by the pro forma adjustments. The tax rate applied is based upon the effective tax rate of Platform for the historical period presented of 30.4% and for the period ended June 30, 2014. This rate was as Arysta’s historical rate is not meaningful for purposes of pro forma adjustments.
 
 
 

 
 
Bonds Adjustments
 
BA
Reflects the anticipated issuance of $900 million of Bonds to fund a portion of the Arysta purchase price, net of deferred financing fees of $15.8 million.

BB 
Reflects the interest expense related to the Bonds anticipated to be issued to fund a portion for the cash purchase price for the Arysta Acquisition comprised of the following:
 
• 
Interest on the $900 million of bonds anticipated to be issued at a rate a fixed rate of approximately 6.25%.
 
• 
Amortization of estimated deferred financing fees of $15.7 million over the anticipated 8 year term of the bonds.
 
 
 

 
 
BC
Reflects income tax benefit (expense) related to the income (loss) before income taxes, non-controlling interests, and accrued payment-in-kind dividends on cumulative preferred shares generated by the pro forma adjustments. The tax rate applied is based on the effective tax rate of Platform for the historical period of 30.4%, as the historical tax rate of Arysta is not meaningful for pro forma adjustments.
 
Common Stock Adjustments
 
UA
Reflects the anticipated issuance of 14.4 million shares of Platform common stock, $.01 par, for proceeds of $340 million, which is net of fees of $10.5 million.
 
Term Debt Adjustments
 
TA 
Reflects Incremental Term Debt to be issued to finance a portion of the cash purchase price of Arysta, net of estimated original issue discount of $11 million.

TB
Reflects the deferred financing costs, of $9.8 million and expenses of $3.9 million related to the anticipated Incremental Term Debt to finance a portion of the Arysta purchase price and for access to an incremental $125 million of revolving line of credit anticipated to be obtained in conjunction with the Arysta Acquisition.

TC
Reflects the reclassification of the portion of the anticipated senior term debt to be issued to finance a portion of the cash purchase price of Arysta that amortizes within a year.
 
TD 
Reflects the interest expense related to the anticipated issuance of Incremental Term Debt to fund a portion of the cash purchase price of the Arysta Acquisition comprised of the following
 
Interest on the incremental borrowing under the senior term debt of $1.1 billion at a rate of 4.25% based on the anticipated terms of the credit agreement. The interest rate is based on an applicable margin of 3.25% applied to a LIBOR floor of 1% and is variable in nature. The pre-tax effect of a 1/8% change in effective interest rate would be $1.4 million annually.
 
Amortization of estimated deferred financing fees of $13.8 million and estimated original issuance discount of $11 million over the anticipated 7 year term of the senior term debt and 4 year term of the revolving line of credit.
 
TE
Reflects income tax benefit (expense) related to the income (loss) before income taxes, non-controlling interests, and accrued payment-in-kind dividends on cumulative preferred shares generated by the pro forma adjustments.  The tax rate applied is based on the effective tax rate of Platform for the historical period June 30, 2014 of 30.4%, as the historical tax rate of Arysta is not meaningful for pro forma adjustments.
 
 
 

 
 
MacDermid Adjustments
 
MA
Reflects elimination of manufacturer's profit in inventory adjustment in connection with MacDermid of $23.9 million for the year ended December 31, 2013.

MB
Reflects incremental depreciation expense in connection with fair value increases to fixed assets resulting from the MacDermid Acquisition.
 
 
MC 
Reflects elimination of stock based compensation expense for director options that vested upon closing of the MacDermid Acquisition.
 
 
MD
Reflects elimination of predecessor stock based compensation expense for awards that vested upon closing of the MacDermid Acquisition.
 
 
ME
Reflects elimination of non-recurring MacDermid acquisition-related expenses, including but not limited to financial advisory, legal and accounting fees recorded during the year ended December 31, 2013.
 
 
MF
Reflects elimination of recorded amortization expenses on MacDermid’s intangible assets.
 
 
MG
Reflects amortization expense associated with the estimated fair value of the intangible assets of MacDermid based on an outside valuation by a third party obtained by Platform subsequent to closing as follows:
 
 
 
(In thousands)
             
 
Intangible Assets
 
Estimated Fair Value
   
Annual Amortization
   
 
Trade names-indefinite lives
  $ 70,800     $    
 
Technology (7-10 years)
  $ 164,200     $ 19,800    
 
Customer relationships (8-20 years)
  $ 494,000     $ 37,700    
 
 
Annual amortization is calculated as estimated fair value divided by the calculated life of the related asset.
 
 
MH
Reflects Platform’s recording of a one-time, non-cash expense of $172 million upon the closing of the MacDermid Acquisition, which represents the fair value of the founder preferred share dividend rights at that time. As this will not have an ongoing impact on the statement of operations, it is presented as an adjustment in the pro forma statements of operations. This estimate was calculated using a Monte Carlo simulation that simulates the daily price of shares over the potential dividend period with an estimate of volatility and interest to arrive at an estimated fair value of future dividend payments as of October 31, 2013.
 
 
MI
Reflects the elimination of recorded interest expense at MacDermid for indebtedness not assumed at closing.
 
MJ 
Reflects interest expense related to indebtedness assumed in the MacDermid Acquisition comprised of the following:
 
Interest on the first lien debt of $753 million at a rate of approximately 4% based on the terms of the credit agreement. Such interest rate is based on an applicable margin of 3% applied to a LIBOR floor of 1% and is variable in nature.  The pre-tax effect of a 1/8% change effective interest rate would be $0.9 million annually.
 
• 
Amortization of deferred financing fees of $1.8 million for the first lien term debt over the five year life of the loan.
 
• 
Interest on other assumed indebtedness ($44,000 of interest annually).

MK
Reflects income tax benefit (expense) related to the income (loss) before income taxes, non-controlling interests, and accrued payment-in-kind dividends on cumulative preferred shares generated by the pro forma adjustments.  The tax rate applied is based upon the estimated applicable statutory tax rates. The Company’s estimated United States statutory tax rate of approximately 38% was applied to interest expense in the United States, where the debt resides as well as to the portion of acquisition costs which were incurred in the United States and to stock compensation. Additionally, the applicable blended rates were applied to inventory, amortization, depreciation, and predecessor stock compensation.
 
 
 

 
 
ML
Reflects the non-controlling interest represented by equity interests in a subsidiary of Platform provided as a portion of the consideration of the MacDermid Acquisition. Such equity interest represents 6.76% of MacDermid multiplied by the pro forma MacDermid pro forma adjustments excluding the adjustments in Note MD, ME, and MH that relate to Platform expenses.
 
 
MM
Reflects the elimination of dividends paid to sellers for an equity interest which has been repaid and eliminated in conjunction with the MacDermid Acquisition.

Weighted Average Share Adjustments

SA
Represents the number of Platform ordinary shares outstanding at January 1, 2014 (which were converted into shares of Platform common stock upon our domestication) plus 2 million shares of Platform common stock issued in exchange for the remaining outstanding equity interests of MacDermid owned by the MacDermid 401K Plan during 2014, 16 million warrants exercised during 2014, 2 million shares issued in connection with the CAS Acquisition, 25.5 million shares issued or to be issued for general corporate purposes, and 14.4 million shares anticipated to be issued in connection with common stock offering.
 
   
SB
Represents the basic shares described in Note SA. Because the pro forma statement of operations reflects a loss, the amount excludes all potentially dilutive common stock.
 
SC
Represents 88.5 million Platform ordinary shares issued in Platform’s initial public offering (which were converted into shares of Platform common stock upon our domestication) plus 14 million Platform ordinary shares (which were converted into shares of Platform common stock upon our domestication ) issued in connection with Platform’s warrant exchange offer (the proceeds of which were used to fund a portion of the cash consideration for the MacDermid Acquisition), 2 million shares of Platform common stock issued in exchange for the remaining outstanding equity interests of MacDermid owned by the MacDermid 401K Plan, 2 million shares expected to be issued in connection with the CAS Acquisition, 25.5 million shares issued or to be issued for general corporate purposes, and 14.4 million shares anticipated to be issued in connection with common stock offering.

SD
Represents the number of basic shares as described in Note SC. Because the pro forma statement of operations reflects a loss, the amount excludes all potential dilutive common stock.